N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.

Monoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of numerous different protein variants and modifications. N-glycosylation as one of the most complex post-translational modification influences the structural characteristics of the antibodies Fc part thereby potentially modulating effector function and pharmacokinetics. Several investigations on the relationship between N-glycosylation and pharmacokinetics have been published. However, this structure-function relationship is not fully understood. In this review potential alterations with focus on N-glycosylation of mAbs and Fc fusion proteins and the possible effects on the pharmacokinetics are reviewed and the current understandings of the underlying mechanisms are described.

[1]  Brittney Livingston,et al.  Real‐time product attribute control to manufacture antibodies with defined N‐linked glycan levels , 2015, Biotechnology progress.

[2]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[3]  Lawrence W. Dick,et al.  Isomerization in the CDR2 of a monoclonal antibody: Binding analysis and factors that influence the isomerization rate , 2010, Biotechnology and bioengineering.

[4]  R. Bischoff,et al.  Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology. , 1994, Journal of chromatography. B, Biomedical applications.

[5]  Wolfgang Lindner,et al.  Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis. , 2011, Journal of chromatography. A.

[6]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[7]  Lai-Xi Wang,et al.  Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. , 2011, Journal of the American Chemical Society.

[8]  Gregory C Flynn,et al.  Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry. , 2007, Analytical biochemistry.

[9]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[10]  Johannes Kneer,et al.  Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. , 2007, Glycobiology.

[11]  C. Ries,et al.  GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab , 2012, Clinical Cancer Research.

[12]  Ming Li,et al.  Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms* , 2008, Journal of Biological Chemistry.

[13]  P. Parren,et al.  Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. , 2012, Analytical biochemistry.

[14]  J. M. Beals,et al.  In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. , 2005, Analytical chemistry.

[15]  David Passmore,et al.  Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor , 2006, Nature Biotechnology.

[16]  M Goodall,et al.  The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. , 2000, Molecular immunology.

[17]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[18]  Stacey Ma,et al.  Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[19]  B. Domon,et al.  Capillary electrophoresis/electrospray ion trap mass spectrometry for the analysis of negatively charged derivatized and underivatized glycans. , 2002, Rapid communications in mass spectrometry : RCM.

[20]  Yang Wang,et al.  Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. , 2011, Molecular immunology.

[21]  Andrew M Goetze,et al.  Rates and impact of human antibody glycation in vivo. , 2012, Glycobiology.

[22]  Stephen P. Young,et al.  Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding* , 2001, The Journal of Biological Chemistry.

[23]  Qiang Qin,et al.  High-throughput immunoglobulin G N-glycan characterization using rapid resolution reverse-phase chromatography tandem mass spectrometry. , 2009, Analytical biochemistry.

[24]  Lora Hamuro,et al.  The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris , 2012, Pharmaceutical Research.

[25]  S. Cohen,et al.  Antibody structure , 2006 .

[26]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[27]  O. Salas-Solano,et al.  On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies. , 2008, Analytical chemistry.

[28]  Alain Beck,et al.  GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins , 2010, Expert opinion on drug discovery.

[29]  Janice M. Reichert,et al.  Marketed therapeutic antibodies compendium , 2012, mAbs.

[30]  Huijuan Li,et al.  Pharmacological significance of glycosylation in therapeutic proteins. , 2009, Current opinion in biotechnology.

[31]  Naoyuki Taniguchi,et al.  Capillary electrophoresis-electrospray ionization mass spectrometry for rapid and sensitive N-glycan analysis of glycoproteins as 9-fluorenylmethyl derivatives. , 2008, Glycobiology.

[32]  D. Harvey,et al.  Reversed-phase ion-pairing liquid chromatography/ion trap mass spectrometry for the analysis of negatively charged, derivatized glycans. , 2003, Rapid communications in mass spectrometry : RCM.

[33]  R. Bass,et al.  N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies , 2011, The Journal of Biological Chemistry.

[34]  P. Bondarenko,et al.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.

[35]  P. Sun,et al.  Recognition of immunoglobulins by Fcgamma receptors. , 2002, Molecular immunology.

[36]  R. Stockert,et al.  The asialoglycoprotein receptor: relationships between structure, function, and expression. , 1995, Physiological reviews.

[37]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[38]  F. Sörgel,et al.  N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical , 2015, Pharmaceutical Research.

[39]  M. Lieber,et al.  The Mechanism of Human Nonhomologous DNA End Joining* , 2008, Journal of Biological Chemistry.

[40]  Reb J. Russell,et al.  Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping. , 2011, Journal of chromatography. A.

[41]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[42]  R. Bayer,et al.  The impact of glycosylation on monoclonal antibody conformation and stability , 2011, mAbs.

[43]  M. Nussenzweig,et al.  Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis , 2002, Science.

[44]  Zhongqi Zhang,et al.  Naturally occurring glycan forms of human immunoglobulins G1 and G2. , 2010, Molecular immunology.

[45]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[46]  A. Deelder,et al.  Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. , 2008, Analytical chemistry.

[47]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[48]  Wolfgang Lindner,et al.  HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals , 2010, Analytical and bioanalytical chemistry.

[49]  Douglas S Rehder,et al.  Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. , 2005, Analytical chemistry.

[50]  R. Hansen,et al.  Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.

[51]  Ilja Ritamo,et al.  Nanoscale reversed-phase liquid chromatography–mass spectrometry of permethylated N-glycans , 2013, Analytical and Bioanalytical Chemistry.

[52]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[53]  Samuel Moser,et al.  Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II , 2006, Biotechnology and bioengineering.

[54]  P. Sun,et al.  Recognition of immunoglobulins by Fcγ receptors , 2002 .

[55]  Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals , 2011, Analytical and bioanalytical chemistry.

[56]  Damian Houde,et al.  Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.

[57]  Marcella Yu,et al.  Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans , 2012, mAbs.

[58]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[59]  Randal R Ketchem,et al.  Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype , 2008, Electrophoresis.

[60]  F. Sörgel,et al.  Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins , 2014, mAbs.

[61]  Jean-Luc Teillaud,et al.  Impact of Glycosylation on Effector Functions of Therapeutic IgG † , 2010, Pharmaceuticals.

[62]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[63]  J. Hochman,et al.  Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[64]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[65]  K. Anumula New high-performance liquid chromatography assay for glycosyltransferases based on derivatization with anthranilic acid and fluorescence detection. , 2012, Glycobiology.

[66]  M. Newkirk,et al.  Differential clearance of glycoforms of IgG in normal and autoimmune‐prone mice , 1996, Clinical and experimental immunology.

[67]  Thomas M. Dillon,et al.  Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass* , 2008, Journal of Biological Chemistry.

[68]  H. Spiegelberg,et al.  The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses. , 1968, Biochemistry.

[69]  F. Sörgel,et al.  Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals , 2013, Analytical and Bioanalytical Chemistry.

[70]  A. Deelder,et al.  Normal-phase nanoscale liquid chromatography-mass spectrometry of underivatized oligosaccharides at low-femtomole sensitivity. , 2004, Analytical chemistry.

[71]  Hongcheng Liu,et al.  Disulfide bond structures of IgG molecules , 2012, mAbs.

[72]  Heide Kogelberg,et al.  Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. , 2007, Glycobiology.

[73]  David Ouellette,et al.  Increased serum clearance of oligomannose species present on a human IgG1 molecule , 2012, mAbs.

[74]  Akira Okazaki,et al.  Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. , 2007, Journal of biotechnology.

[75]  Stuart M Haslam,et al.  Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. , 2012, Nature chemical biology.

[76]  Kurt Forrer,et al.  Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[77]  Hai Pan,et al.  C‐terminal lysine processing of human immunoglobulin G2 heavy chain in vivo , 2011, Biotechnology and bioengineering.

[78]  S. Iida,et al.  Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model , 2008, Cancer Immunology, Immunotherapy.

[79]  D. Aswad,et al.  Isoaspartate in peptides and proteins: formation, significance, and analysis. , 2000, Journal of pharmaceutical and biomedical analysis.

[80]  Lihua Huang,et al.  Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. , 2006, Analytical biochemistry.

[81]  K R Anumula,et al.  High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. , 1998, Glycobiology.

[82]  R. Ghirlando,et al.  Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. , 2001, The Journal of biological chemistry.

[83]  Hongcheng Liu,et al.  Glutamine deamidation of a recombinant monoclonal antibody. , 2008, Rapid communications in mass spectrometry : RCM.

[84]  G. Gregoriadis,et al.  The role of sialic acid in determining the survival of glycoproteins in the circulation. , 1971, The Journal of biological chemistry.

[85]  G. Ashwell,et al.  Carbohydrate-specific receptors of the liver. , 1982, Annual review of biochemistry.

[86]  T. Wurch,et al.  Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.

[87]  K. Kuma,et al.  The Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain Variable Region Locus , 1998, The Journal of experimental medicine.

[88]  S. Gordon,et al.  The mannose receptor: linking homeostasis and immunity through sugar recognition. , 2005, Trends in immunology.

[89]  P. Allavena,et al.  From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. , 2004, Critical reviews in immunology.

[90]  Gregory C Flynn,et al.  The effect of Fc glycan forms on human IgG2 antibody clearance in humans. , 2008, Glycobiology.

[91]  J. Prestegard,et al.  NMR Analysis Demonstrates Immunoglobulin G N-glycans are Accessible and Dynamic , 2011, Nature chemical biology.

[92]  Eric Ezan,et al.  Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. , 2009, Bioanalysis.

[93]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[94]  M. Retter,et al.  Impact of Glycation on Antibody Clearance , 2014, The AAPS Journal.

[95]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.